EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice

Elinor Willis, Jillian Verrelle, Esha Banerjee, Charles-Antoine Assenmacher iD, James C Tarrant, Nicholas Skuli, Moriah L Jacobson, Donald M O'Rouke, Zev A Binder, Enrico Radaelli iD

Veterinary Pathology · 2024-07 · 61 (4) · 664-674

DOI: 10.1177/03009858231222216 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Veterinary Pathology, online erschienen am 10.01.2024. Verfasst von Elinor Willis und 9 weiteren Autor:innen. Beteiligte Einrichtung: Comparative Pathology Core, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Hematopoietic Stem Cells, Antigens, CD34, Hematopoietic Stem Cell Transplantation, Myeloid Cells. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIH HHS, abramson cancer center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NSG-SGM3 and NOG-EXL mice combine severe immunodeficiency with transgenic expression of human myeloid stimulatory cytokines, resulting in marked expansion of myeloid populations upon humanization with CD34+ hematopoietic stem cells (HSCs). Humanized NSG-SGM3 mice typically develop a lethal macrophage activation syndrome and mast cell hyperplasia that limit their use in long-term studies (e.g., humanization followed by tumor xenotransplantation). It is currently unclear to what extent humanized NOG-EXL mice suffer from the same condition observed in humanized NSG-SGM3 mice. We compared the effects of human CD34+ HSC engraftment in these two strains in an orthotopic patient-derived glioblastoma model. NSG-SGM3 mice humanized in-house were compared to NOG-EXL mice humanized in-house and commercially available humanized NOG-EXL mice. Mice were euthanized at humane or study endpoints, and complete pathological assessments were performed. A semiquantitative multiparametric clinicopathological scoring system was developed to characterize chimeric myeloid cell hyperactivation (MCH) syndrome. NSG-SGM3 mice were euthanized at 16 weeks after humanization because of severe deterioration of clinical conditions. Humanized NOG-EXL mice survived to the study endpoint at 22 weeks after humanization and showed less-severe MCH phenotypes than NSG-SGM3 mice. Major differences included the lack of mast cell expansion and limited tissue/organ involvement in NOG-EXL mice compared to NSG-SGM3 mice. Engraftment of human lymphocytes, assessed by immunohistochemistry, was similar in the two strains. The longer survival and decreased MCH phenotype severity in NOG-EXL mice enabled their use in a tumor xenotransplantation study. The NOG-EXL model is better suited than the NSG-SGM3 model for immuno-oncology studies requiring long-term survival after humanization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem CellsAntigens, CD34Hematopoietic Stem Cell TransplantationMyeloid CellsMice, TransgenicAnimalsMiceHumansPhenotypeDisease Models, Animal

Stichwörter der Autor:innen

NOG-EXLNSG-SGM3hemophagocytic lymphohistiocytosishuman hematopoietic stem cellshumanizationmacrophage activation syndromemast cell hyperplasiamouse

Substanzen

Antigens, CD34

Autor:innen und Institutionen

  • Comparative Pathology Core, Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA.
  • GlaxoSmithKline, Collegeville, PA.
  • Stem Cell and Xenograft Core, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
  • Taconic Biosciences, Inc., Rensselaer, NY.
  • Department of Neurosurgery, Perelman School of Medicine, GBM Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.

ORCID-Profile: Charles-Antoine Assenmacher, Enrico Radaelli

Förderung

  • NCI NIH HHS
  • NIH HHS
  • abramson cancer center
  • GBM Translational Center of Excellence
  • Penn Vet IIZD Core pilot grant opportunity 2022
  • NIH Shared Instrumentation

Zitieren

APA

Willis, E., Verrelle, J., Banerjee, E., Assenmacher, C. A., Tarrant, J. C., Skuli, N., Jacobson, M. L., O'Rouke, D. M., Binder, Z. A., & Radaelli, E. (2024). Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice. Veterinary Pathology, 61(4), 664-674. https://doi.org/10.1177/03009858231222216

Vancouver

Willis E, Verrelle J, Banerjee E, Assenmacher CA, Tarrant JC, Skuli N, et al. Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice. Veterinary Pathology. 2024;61(4):664-674. doi:10.1177/03009858231222216

BibTeX
@article{Willis2024,
  author = {Willis, Elinor and Verrelle, Jillian and Banerjee, Esha and Assenmacher, Charles-Antoine and Tarrant, James C and Skuli, Nicholas and Jacobson, Moriah L and O'Rouke, Donald M and Binder, Zev A and Radaelli, Enrico},
  title = {Humanization with CD34-positive hematopoietic stem cells in NOG-EXL mice results in improved long-term survival and less severe myeloid cell hyperactivation phenotype relative to NSG-SGM3 mice},
  journal = {Veterinary Pathology},
  year = {2024},
  volume = {61},
  number = {4},
  pages = {664--674},
  doi = {10.1177/03009858231222216}
}
Kostenlos starten →